Orthodontics for Immunosuppressed Patients: What to Expect in the UK

What immunosuppression means for orthodontic treatment

Immunosuppression describes a state in which the body's immune response is reduced — either by disease or by medication taken to prevent organ rejection, manage autoimmune conditions, or treat cancer. For orthodontics, the immune system is central to the process: tooth movement depends on an inflammatory response in the periodontal ligament that drives bone remodelling. Immunosuppression can slow this process, increase infection susceptibility, impair healing, and cause drug-related tissue changes such as gingival overgrowth. None of these factors necessarily rules out orthodontic treatment, but they require a modified approach, careful patient selection, and shared care with the prescribing physician or specialist.

Organ transplant recipients — timing and medication effects

Organ transplant recipients face two distinct phases relevant to orthodontics. In the first year post-transplant, the risk of rejection is highest and immunosuppressant doses are at their peak. Elective orthodontic treatment is best deferred until the patient is medically stable and the transplant team agrees that the immune system is sufficiently controlled. Beyond the first year, many patients reach a stable maintenance phase in which carefully planned orthodontic treatment becomes feasible. Cyclosporin — used widely in kidney, liver, and heart transplant patients — causes gingival hyperplasia (overgrowth of gum tissue) in 25 to 30% of patients. This can mask plaque accumulation, increase inflammation risk, and in severe cases require gingivectomy before or during orthodontic treatment. Tacrolimus, the alternative to cyclosporin, has a much lower rate of gingival side effects and may be preferable from an orthodontic perspective, though the decision rests with the transplant team.

HIV on antiretroviral therapy — treatment feasibility and periodontal stability

Patients living with HIV who are stable on antiretroviral therapy (ART) and have an undetectable viral load are generally suitable candidates for orthodontic treatment, provided their periodontal health is satisfactory. HIV itself does not preclude tooth movement, and modern ART has transformed the prognosis for patients to the point where long-term orthodontic planning is entirely appropriate. The key pre-treatment requirements are: a CD4 count that has been discussed and approved by the HIV specialist; periodontal stability with no active disease; and the patient's dental team being informed of the diagnosis to ensure appropriate infection control protocols. Periodontal disease is more prevalent and can progress more rapidly in HIV-positive individuals, so periodontal review should precede and accompany orthodontic treatment.

Chemotherapy and timing of orthodontic treatment

Active chemotherapy is a contraindication to elective orthodontic treatment. Chemotherapy suppresses bone marrow function, reducing white cell counts and platelet levels and dramatically increasing the risk of infection and bleeding from even minor mucosal trauma caused by brackets and wires. Existing orthodontic appliances should ideally be removed before a chemotherapy course begins, or at minimum the orthodontist and oncology team should agree a management plan. After treatment, the timing of re-starting or commencing orthodontics depends on bone marrow recovery, which the oncology team will monitor. For most patients this means waiting at least three to six months after the final cycle, with the oncologist's clearance required before resuming active tooth movement.

Methotrexate and bone remodelling

Methotrexate is used in low doses for rheumatoid arthritis and other autoimmune conditions, and in high doses for cancer. At low maintenance doses used for autoimmune disease, methotrexate can slow bone remodelling and therefore slow the rate of tooth movement. This is not a contraindication, but it means treatment may take longer and appointment intervals may need to be extended. At higher doses used in oncology, the same constraints that apply to chemotherapy apply. The rheumatologist or oncologist should be consulted before commencing treatment, and the orthodontist should document the medication, dosage, and approval in the patient record.

Infection risk management during active treatment

Fixed braces create surfaces that accumulate plaque and can act as a source of localised infection. For immunosuppressed patients this risk is amplified: periodontal infections can become systemic, and mucosal ulceration from wire ends or broken brackets can develop into more serious lesions. Practical measures include: more frequent review appointments (every four to six weeks rather than the standard eight); using lower force levels to minimise mucosal trauma; ensuring wire ends are always well trimmed; and advising the patient to seek early dental review for any mucosal lesion that does not resolve within two weeks. Some clinicians prefer removable aligners for immunosuppressed patients as they are removed for cleaning and create less plaque-retentive surface area, though compliance and force delivery differ from fixed appliances.

Why is liaison with a specialist physician essential?

Shared care is not optional for immunosuppressed patients — it is a clinical requirement. Before commencing treatment the orthodontist should write to the prescribing physician or specialist team (transplant, rheumatology, oncology, or HIV clinic) to confirm that orthodontic treatment is appropriate, to understand current medication doses and any planned changes, and to agree on an escalation pathway if problems arise during treatment. Antibiotic prophylaxis is not routinely required for orthodontic procedures in the UK, but the physician's view should be sought, particularly for patients who are significantly neutropenic or who have additional cardiac risk factors.

Why does oral hygiene matter more for immunosuppressed patients?

Outstanding oral hygiene is a prerequisite, not a recommendation, for immunosuppressed patients undergoing orthodontic treatment. Before bonding brackets, the patient should demonstrate consistent plaque control over at least two consecutive visits. Electric toothbrushing, interdental brushes, and fluoride mouthwash should be standard. The dentist and hygienist should be involved at the start of treatment and throughout, with professional cleaning appointments aligned to orthodontic review visits where possible. If oral hygiene deteriorates during treatment, active tooth movement should be paused until it is restored.

NHS vs private access for immunosuppressed patients

Immunosuppressed patients who are under 18 and meet the IOTN threshold are entitled to NHS orthodontic treatment in the same way as other patients. However, the increased complexity of their care — including the need for specialist liaison, more frequent appointments, and possible removal and re-bonding of appliances around medical events — often means that specialist orthodontists in secondary care or hospital dental services are better placed to manage their treatment than standard NHS primary care contracts. Adults will generally need to fund treatment privately, though some teaching hospital orthodontic departments accept complex adult cases for supervised training purposes. Fees for immunosuppressed patients are not formally higher, but longer treatment times increase overall cost.

Useful related pages

This guide is for general information only. It is not a diagnosis, treatment plan, or substitute for advice from a registered dentist or orthodontist.